These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 9844807)

  • 1. An improved and updated version of the compact procedure for the evaluation of P450-mediated chemical activation.
    Lewis DF; Ioannides C; Parke DV
    Drug Metab Rev; 1998 Nov; 30(4):709-37. PubMed ID: 9844807
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular modeling of enzymes and receptors involved in carcinogenesis: QSARs and compact-3D.
    Lewis DF; Moereels H; Lake BG; Ioannides C; Parke DV
    Drug Metab Rev; 1994; 26(1-2):261-85. PubMed ID: 8082570
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins.
    Gonzalez FJ; Gelboin HV
    Drug Metab Rev; 1994; 26(1-2):165-83. PubMed ID: 8082563
    [No Abstract]   [Full Text] [Related]  

  • 4. [Metabolic activation of chemical carcinogens by cytochrome P-450].
    Kawajiri K
    Tanpakushitsu Kakusan Koso; 1988 Feb; 33(2):167-73. PubMed ID: 3393690
    [No Abstract]   [Full Text] [Related]  

  • 5. Microsomal N- and C-oxidations of carcinogenic aromatic amines and amides.
    Lotlikar PD; Hong YS
    Natl Cancer Inst Monogr; 1981 Dec; (58):101-7. PubMed ID: 7341966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of the cytochrome P450 system as a mechanism of chemoprotection.
    Wolf CR; Mahmood A; Henderson CJ; McLeod R; Manson MM; Neal GE; Hayes JD
    IARC Sci Publ; 1996; (139):165-73. PubMed ID: 8923029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of mutagens by human cytochrome P-450 enzymes.
    Guengerich FP; Shimada T; Iwasaki M; Martin MV
    Prog Clin Biol Res; 1990; 340B():87-96. PubMed ID: 2168051
    [No Abstract]   [Full Text] [Related]  

  • 8. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.
    Wolf CR
    IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanism of cyclosporine A drug interactions: inducers and inhibitors of cytochrome P450 screening in primary cultures of human hepatocytes.
    Pichard L; Fabre JM; Domergue J; Fabre G; Saint-Aubert B; Mourad G; Maurel P
    Transplant Proc; 1991 Feb; 23(1 Pt 2):978-9. PubMed ID: 1989351
    [No Abstract]   [Full Text] [Related]  

  • 10. Oltipraz-mediated changes in aflatoxin B(1) biotransformation in rat liver: implications for human chemointervention.
    Buetler TM; Bammler TK; Hayes JD; Eaton DL
    Cancer Res; 1996 May; 56(10):2306-13. PubMed ID: 8625305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The duration of induction and species influences the downregulation of cytochrome P450 by the interferon inducer polyinosinic acid-polycytidylic acid.
    Anari MR; Cribb AE; Renton KW
    Drug Metab Dispos; 1995 May; 23(5):536-41. PubMed ID: 7587927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contributions of two inducible forms of cytochrome P-450 in rat liver microsomes to the metabolic activation of various chemical carcinogens.
    Kawajiri K; Yonekawa H; Gotoh O; Watanabe J; Igarashi S; Tagashira Y
    Cancer Res; 1983 Feb; 43(2):819-23. PubMed ID: 6401224
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanism and structure-reactivity relationships for aromatic hydroxylation by cytochrome P450.
    Bathelt CM; Ridder L; Mulholland AJ; Harvey JN
    Org Biomol Chem; 2004 Oct; 2(20):2998-3005. PubMed ID: 15480465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of cytochrome P450 enzyme induction in the metabolic activation of benzo[c]phenanthrene in human cell lines and mouse epidermis.
    Einolf HJ; Story WT; Marcus CB; Larsen MC; Jefcoate CR; Greenlee WF; Yagi H; Jerina DM; Amin S; Park SS; Gelboin HV; Baird WM
    Chem Res Toxicol; 1997 May; 10(5):609-17. PubMed ID: 9168260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative structure-activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1).
    Lewis DF
    Drug Metab Rev; 1997 Aug; 29(3):589-650. PubMed ID: 9262943
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunochemical study on the role of different types of microsomal cytochrome P-450 in mutagenesis by chemical carcinogens.
    Kawajiri K; Yonekawa H; Harada N; Noshiro M; Omura T; Tagashira Y
    Cancer Res; 1980 May; 40(5):1652-7. PubMed ID: 6768451
    [No Abstract]   [Full Text] [Related]  

  • 17. Participation of phenobarbital-inducible cytochrome P450 in the mutagenic activation of N-nitrosopropylamines by liver and lung 9000 g fractions from five animal species and man.
    Mori Y; Konishi Y
    IARC Sci Publ; 1991; (105):398-403. PubMed ID: 1855888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computer prediction and experimental validation of cytochrome P4502D6-dependent oxidation of GBR 12909.
    de Groot MJ; Bijloo GJ; Hansen KT; Vermeulen NP
    Drug Metab Dispos; 1995 Jun; 23(6):667-9. PubMed ID: 7587951
    [No Abstract]   [Full Text] [Related]  

  • 19. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy.
    Guengerich FP
    Cancer Res; 1988 Jun; 48(11):2946-54. PubMed ID: 3284639
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?
    Tang C; Lin JH; Lu AY
    Drug Metab Dispos; 2005 May; 33(5):603-13. PubMed ID: 15673596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.